SCHEMBL5149502

SCHEMBL5149502

CSc1ccc(C2SCC(=O)N2CCc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.56
ALDH1A1 P00352 7/20 0.55
GAA P10253 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HPGD P15428 3/20 0.47
PKM P14618 2/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 3/20 0.46
KCNA5 P22460 1/20 0.46
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155489 0.90 ALDH1A1 (0.56) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5151382 0.82 ALDH1A1 (0.54) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5151414 0.79 ACHE (0.56) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5156963 0.78 ALDH1A1 (0.52) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5155140 0.77 ALDH1A1 (0.49) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5152300 0.76 HCRTR1 (0.56) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5151502 0.76 MGAM (0.47) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5152128 0.75 ALDH1A1 (0.48) MGAMALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL5156712 0.74 GAA (0.60) ALDH1A1GAAL3MBTL1SMN1; SMN2KDM4E
SCHEMBL5156369 0.72 CACNA1B (0.65) ALDH1A1GAAL3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MGAM 2524/4885ALDH1A1 3381/4885GAA 3548/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MGAM 3677/4885ALDH1A1 1370/4885GAA 3419/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MGAM 3677/4885ALDH1A1 1370/4885GAA 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.